|Bid||10.16 x 1800|
|Ask||10.75 x 4000|
|Day's Range||10.41 - 10.45|
|52 Week Range||9.77 - 11.84|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A biotechnology firm that researches and manufactures ribonucleic acid, or RNA, for use in human and plant health is expanding its footprint in Research Triangle Park ahead of the expected approval of its first product and its entrance onto the public markets. Massachusetts-based GreenLight Biosciences started research and development in RTP for the plant health side of its business near the beginning of the Covid-19 pandemic. About two years later, the company is expanding into a facility that includes 40,000 square feet of lab and office space and 15,000 square feet of greenhouse space.
GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion. GreenLight is merging with Environmental Impact Acquisition Corp (NASDAQ: ENVI), which is backed by investment bank Canaccord Genuity Group Inc. GreenLight's ribonucleic acid (RNA) platform has developed candidates for COVID-19, influenza, and earlier-stage programs in sickle cell disease. It is simultaneously working on RNA-based su
Every investor in Environmental Impact Acquisition Corp. ( NASDAQ:ENVI ) should be aware of the most powerful...